key: cord-0917321-oq4cogks authors: Li, Hanlin; Radhakrishnan, Jai title: A pharmacist‐physician collaborative care model in chronic kidney disease date: 2021-10-26 journal: J Clin Hypertens (Greenwich) DOI: 10.1111/jch.14372 sha: 773257b9dae6bc4b2970a6ae47f9175d8ac656ea doc_id: 917321 cord_uid: oq4cogks A multidisciplinary approach, including pharmacist interventions, has improved clinical outcomes and reduced economic costs in chronic disease management. To our knowledge, this is the first study to describe the incorporation of pharmacist‐driven medication management with partnering nephrologists while capitalizing on technology to improve outcomes in a Chronic kidney disease (CKD) population. The authors created a collaborative drug therapy management agreement to enhance medication management for hypertension and diabetes mellitus. Our metrics aligned with the Healthcare Effectiveness Data and Information Set (HEDIS) measures. Most referrals to the program met the HEDIS definition of suboptimal disease control (Diabetes: 19/25 and Hypertension: 45/70). In patients with multiple pharmacy visits, achievement of diabetes targets increased from 23% to 67% and hypertension from 29% to 58%. Those who used technology tools were more likely to reach goals. The positive impact of a pharmacist‐physician collaboration and utilization of technology tools present an opportunity to improve care for CKD patients. In patients with multiple pharmacy visits, achievement of diabetes targets increased from 23% to 67% and hypertension from 29% to 58%. Those who used technology tools were more likely to reach goals. The positive impact of a pharmacist-physician collaboration and utilization of technology tools present an opportunity to improve care for CKD patients. clinical pharmacology, diabetes mellitus, hypertension, outcomes of care, technology Chronic kidney disease (CKD) is a public health concern given its prevalence, associated morbidity, and mortality risk. 1 The pharmacist created a collaborative drug therapy management agreement with nephrologists to optimize medication management for greater than 90 mm Hg, whereas controlled is when SBP is less than 140 mm Hg and DBP is less than 90 mm Hg. 10 Guideline recommendations were taken into consideration when developing individualized patient goals. 11, 12 Additionally, inadequate diabetes control has a cutoff of a hemoglobin A1c greater than 9%, and the goal is an A1c less than 8%. 10 We performed an IRB-approved, retrospective study to evaluate the program. Our patient characteristics and consult reasons are summarized in We tracked real-time goal attainment rates in our dashboard to optimize clinic utilization (Figure 1 ). The positive impact of a pharmacist-physician collaboration presents an opportunity to optimize care for CKD patients. With the National Kidney Initiative and a focus on a value-based model, incorporating a team-based approach is needed to enhance the services and improve outcomes in this vulnerable population. 13 The success of the pharmacist-physician collaboration is observed as the role of team members evolved. 14 Given healthcare complexity continues to increases, it is crucial to recognize the need to synergize efforts to maximize efficiency across the spectrum of care. We observed that utilizing technology tools was feasible and patients who used such tools were more likely to achieve goals. 15 Long-term outcomes, including progression of disease and healthcare F I G U R E 1 Dashboard outcome metrics. The illustrations are for diabetes and hypertension HEDIS measures target achievement rates. For each disease state, the first diagram shows the % at goal for those with pharmacist referral and seen two or more times; the second diagram shows the % at goal at the time of referral or the initial pharmacy visit; the third diagram shows the % at goal with no pharmacy referrals utilization, are to be assessed in a prospective, randomized trial to validate the efficacy of pharmacy services and technology. Further analysis is needed to confirm key drivers of patient activation and associated impact on outcomes. None declared. None. All authors have reviewed and approved the contents of the manuscript; Hanlin Li and Jai Radhakrishnan implemented the program and carried out the workflow. Hanlin Li analyzed the data and drafted a significant portion of the manuscript. Jai Radhakrishnan supervised the final manuscript. Hanlin Li PharmD, MBA, BCACP https://orcid.org/0000-0002-6508-145X Effectiveness of pharmacist intervention model for chronic kidney disease patients; a prospective comparative study Pharmacist-led chronic disease management: a systematic review of effectiveness and harms compared to usual care Pharmacist intervention for blood pressure control in patients with diabetes and/or chronic kidney disease A pharmacist based intervention to improve the care of patients with CKD: a pragmatic, randomized, controlled trial A cluster-randomized trial of a physician∖pharmacist collaborative model to improve blood pressure control Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms Evaluating barriers to adopting telemedicine worldwide: a systematic review Using digital health technology to better generate evidence and deliver evidence-based care NYSED.gov Office of the Professions. Education Law Article ACC/AHA/AAPA/ABC/ ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease CMS Kidney Care Choices (KCC) Mode. 2021 Pharm.D.s and M.D.s in the transplant world -friends, foes, competitors or all are in evolution? Improving hypertension control and patient engagement using digital tools How to cite this article: Li H, Radhakrishnan J. A pharmacist-physician collaborative care model in chronic kidney disease